Kazia Therapeutics Ltd ADR
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia. Show More...
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 3.80 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-06 2011-06 2012-06 2013-06 2014-06 2015-06 2016-06 2017-06 2018-06 2019-06 TTM Earnings Per Share AUD -12.1 -6.36 1.28 -0.9 -4.76 -2.99 -2.82 -0.23 -1.24 -1.79 -1.54 Dividends AUD Payout Ratio % * Shares Mil 1.0 1.0 1.0 1.0 2.0 2.0 4.0 47.0 5.0 6.0 6.0 Book Value Per Share * USD 9.23 4.39 7.48 1.94 2.66 0.27 7.21 5.03 3.91 2.17 1.15 Free Cash Flow Per Share * USD -13.84 -9.17 -5.69 -11.29 -2.34 -2.81 -2.66 -2.03 -1.77 -1.25 Return on Assets % -43.22 -40.59 12.06 -13.99 -143.49 -28.11 -29.54 -29.88 -18.85 -41.62 -43.92 Financial Leverage (Average) 1.72 3.01 2.59 1.42 3.08 1.03 1.05 1.42 1.46 1.49 1.67 Return on Equity % -70.81 -84.29 33.98 -27.43 -269.02 -30.92 -30.69 -36.01 -27.09 -61.43 -66.12 Return on Invested Capital % -70.75 -84.13 33.98 -18.25 -141.4 -31.01 -31.72 -34.28 -27.54 -62.01 -66.96 Interest Coverage -607.06 -10.42 -9.59 -104.88 -13.21 Current Ratio 3.21 1.54 2.32 1.84 0.81 25.11 23.81 3.62 2.38 3.96 2.44 Quick Ratio 2.3 1.31 2.18 1.65 0.79 25.01 23.42 3.44 2.13 3.68 2.33 Debt/Equity